Physician profile
David Nery
NPI 1649651217
$13,473.74
in general payments reported to CMS, 2019-2025
23 companies · $3,361 in 2025
The $3,361 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $108 · 2022: $427 · 2023: $2,983 · 2024: $6,453 · 2025: $3,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,813 · Food and Beverage: $3,983 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,813.10 |
| Food and Beverage | $3,982.68 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,426.29 | 2023-2025 | Venaseal, Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $2,582.99 | 2022-2025 | Mitraclip, Jot Dx |
| Boston Scientific Corporation | $2,397.72 | 2022-2024 | Versacross Access Solution, Watchman Flx |
| Edwards Lifesciences Corporation | $1,569.56 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Mitris Resilia Mitral Valve |
| Terumo Medical Corporation | $1,515.21 | 2021-2024 | Glidesheath Slender, Glidewire, Metacross Otw |
| Janssen Pharmaceuticals, INC | $160.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $113.48 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $110.74 | 2019-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $75.40 | 2024 | Arcalyst |
| Pfizer INC. | $67.41 | 2022-2024 | |
| Stryker Corporation | $61.04 | 2025 | Clottriever Bold Catheter, Flowtriever |
| Amgen INC. | $60.40 | 2019-2025 | Repatha, Repatha |
| Abiomed | $60.02 | 2023-2024 | Impella |
| Lantheus Medical Imaging, INC. | $50.98 | 2021 | |
| Lilly USA, LLC | $47.78 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $33.89 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $31.56 | 2024-2025 | Eliquis, Camzyos |
| Penumbra, INC. | $22.17 | 2025 | Indigo System |
| Scpharmaceuticals INC. | $20.53 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.40 | 2023 | Farxiga |
| Cardiva Medical, INC. | $16.96 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.00 | 2024 | Jardiance |
| W. L. Gore & Associates, INC. | $13.80 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.